DEVELOPING NEW KETAMINE THERAPIES
FOR LARGE-MARKET & ORPHAN INDICATIONS
Bexson Biomedical is developing a unique formulation of ketamine for chronic and acute pain disorders.
The opioid crisis is a Public Health Emergency in the United States.
There is a desperate need for safe and potent treatments that can offer
a real alternative to opioid-based pain management to millions of people in pain.
Ketamine offers real solutions to the Pain Problem.
Potency that matches powerful opioids
Pharmacology that can reverse chronic pain
Efficacy across multiple pain sub-types
Highly established safety profile
Why is this medication still unavailable in Chronic Pain Management?
A new delivery system is needed to address the limitations of current ketamine preparations to allow control over dosing and reduced need for monitoring.
Bexson Biomedical is meeting that challenge.
Bexson’s lead project is a novel ketamine delivery system that includes a proprietary formulation of ketamine delivered by a minimally invasive, wearable, subcutaneous infusion pump.
Pain management has not seen meaningful innovation in a long time, even despite the severity national opioid crises. Bexson's new pain treatments will bridge this gap for both rare pain diseases and large market pain indications.
In February 2019 Bexson was granted Orphan Status for ketamine in the treatment of Complex Regional Pain Syndrome, our lead indication. In parallel, we are targeting post operative pain management and other large market indications.
In 2010, . . . as many as 1.6 million patients in the United States could become long-term opioid users each year after ambulatory surgery alone, and as many as 160,000 may develop dependence, abuse, or overdose. (Pino 2019)